Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cormedix Inc (CRMD)

Cormedix Inc (CRMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,345
  • Shares Outstanding, K 26,127
  • Annual Sales, $ 280 K
  • Annual Income, $ -16,430 K
  • 60-Month Beta 3.25
  • Price/Sales 284.35
  • Price/Cash Flow 13.19
  • Price/Book 3.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.23
  • Number of Estimates 2
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -4.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.16 +49.07%
on 03/19/20
5.80 -44.48%
on 03/09/20
-2.61 (-44.77%)
since 03/06/20
3-Month
2.16 +49.07%
on 03/19/20
7.35 -56.19%
on 01/16/20
-3.75 (-53.80%)
since 01/06/20
52-Week
2.16 +49.07%
on 03/19/20
10.14 -68.24%
on 04/08/19
-6.73 (-67.64%)
since 04/05/19

Most Recent Stories

More News
Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%

Editas Medicine (EDIT) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

CRMD : 3.25 (+1.88%)
EDIT : 20.81 (+6.39%)
CorMedix (CRMD) Reports Q4 Loss, Misses Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 12.50% and -73.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

CRMD : 3.25 (+1.88%)
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Company in process of submitting New Drug Application (NDA) for Neutrolin(R) for prevention of catheter-related blood stream infections via a rolling review granted by FDA

CRMD : 3.25 (+1.88%)
CorMedix, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 16, 2020 / CorMedix, Inc. (AMEX:CRMD) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 16, 2020 at 4:30 PM Eastern...

CRMD : 3.25 (+1.88%)
CorMedix Inc. to Report Fourth Quarter 2019 Financial Results and Provide a Corporate Update on March 16

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 3.25 (+1.88%)
Earnings Preview: CorMedix (CRMD) Q4 Earnings Expected to Decline

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRMD : 3.25 (+1.88%)
CorMedix Approved to Sell $5.5 Million of NOL Tax Benefits Through the New Jersey Economic Development Authority Program

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 3.25 (+1.88%)
CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin(R) New Drug Application

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 3.25 (+1.88%)
CorMedix (CRMD) Reports Q3 Loss, Misses Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 12.00% and -68.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CRMD : 3.25 (+1.88%)
CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,...

CRMD : 3.25 (+1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CRMD with:

Business Summary

CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix's goal is to treat kidney disease by reducing the commonly associated cardiovascular...

See More

Key Turning Points

2nd Resistance Point 3.41
1st Resistance Point 3.30
Last Price 3.25
1st Support Level 3.04
2nd Support Level 2.89

See More

52-Week High 10.14
Fibonacci 61.8% 7.09
Fibonacci 50% 6.15
Fibonacci 38.2% 5.21
Last Price 3.25
52-Week Low 2.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar